# EDGAR Filing Document

**Accession Number:** 0000874015
**File Stem:** 0000874015-23-000118
**Filing Date:** 2023-3
**Character Count:** 12225
**Document Hash:** 57dab38091d86546f4ed55efc0a12979
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000874015-23-000118.hdr.sgml**: 20230324

**ACCESSION NUMBER**: 0000874015-23-000118

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230314

**FILED AS OF DATE**: 20230324

**DATE AS OF CHANGE**: 20230324

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Birchler Brian
- **CENTRAL INDEX KEY:** 0001970151

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19125
- **FILM NUMBER:** 23761141

**MAIL ADDRESS:**
- **STREET 1:** C/O IONIS PHARMACEUTICALS, INC.
- **STREET 2:** 2855 GAZELLE COURT
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92010
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IONIS PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0000874015
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 330336973
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2855 GAZELLE COURT
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92010
- **BUSINESS PHONE:** 7609319200

**MAIL ADDRESS:**
- **STREET 1:** 2855 GAZELLE COURT
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ISIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19930328

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Birchler Brian<br><sub>(Last) (First) (Middle)</sub><br>2855 GAZELLE COURT<br><sub>(Street)</sub><br>CARLSBAD, CA 92010<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>IONIS PHARMACEUTICALS INC [ IONS ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-14 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP, Corp and Development Ops_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 35325 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Non-Qualified Stock Option (right to buy) | <sup>(1)</sup> | 2032-01-02 | Common Stock | 19500 | $32.6 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(2)</sup> | 2032-03-19 | Common Stock | 15000 | $35.25 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(3)</sup> | 2033-01-02 | Common Stock | 22942 | $37.58 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(4)</sup> | 2024-01-02 | Common Stock | 26982 | $47.34 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(5)</sup> | 2025-01-01 | Common Stock | 31500 | $49.25 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(6)</sup> | 2026-01-01 | Common Stock | 23900 | $53.77 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(7)</sup> | 2028-01-03 | Common Stock | 22000 | $56.78 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(8)</sup> | 2027-01-01 | Common Stock | 26063 | $60.89 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(9)</sup> | 2024-01-01 | Common Stock | 15500 | $61.57 | D |  |
| Performance Restricted Stock Units<sup>(10)</sup> | <sup>(11)</sup> | <sup>(11)</sup> | Common Stock | 14338 | $0.0 | D |  |
| Restricted Stock Unit<sup>(12)</sup> | 2024-01-15<sup>(13)</sup> | 2024-01-15<sup>(13)</sup> | Common Stock | 2896 | $0.0 | D |  |
| Restricted Stock Unit<sup>(12)</sup> | 2024-01-15<sup>(14)</sup> | 2025-01-15<sup>(14)</sup> | Common Stock | 4888 | $0.0 | D |  |
| Restricted Stock Unit<sup>(12)</sup> | 2024-01-15<sup>(15)</sup> | 2026-01-15<sup>(15)</sup> | Common Stock | 7312 | $0.0 | D |  |
| Restricted Stock Unit<sup>(12)</sup> | 2023-04-15<sup>(16)</sup> | 2026-04-15<sup>(16)</sup> | Common Stock | 7500 | $0.0 | D |  |
| Restricted Stock Unit<sup>(12)</sup> | 2024-01-15<sup>(17)</sup> | 2027-01-15<sup>(17)</sup> | Common Stock | 17207 | $0.0 | D |  |

---

### Footnotes:

(1) Grant on 01/03/2022 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. 25% of the shares subject to the option will be vested and become exercisable on 01/03/2023. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments. The option is exercisable as to 5,687 shares on 03/14/2023.

(2) Grant on 03/20/2022 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. 25% of the shares subject to the option will be vested and become exercisable on 03/20/2023. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments. The option is exercisable as to 0 shares on 03/14/2023.

(3) Grant on 01/03/2023 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. 25% of the shares subject to the option will be vested and become exercisable on 01/03/2024. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments. The option is exercisable as to 0 shares on 03/14/2023.

(4) Grant on 01/03/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. 25% of the shares subject to the option vested and became exercisable on 01/03/2018. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments. The option is exercisable as to 26,982 shares on 03/14/2023.

(5) Grant on 01/02/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. 25% of the shares subject to the option vested and became exercisable on 01/02/2019. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments. The option is exercisable as to 31,500 shares on 03/14/2023.

(6) Grant on 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. 25% of the shares subject to the option vested and became exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments. The option is exercisable as to 23,900 shares on 03/14/2023.

(7) Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. 25% of the shares subject to the option will be vested and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments. The option is exercisable as to 11,916 shares on 03/14/2023.

(8) Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. 25% of the shares subject to the option will be vested and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments. The option is exercisable as to 20,633 shares on 03/14/2023.

(9) Grant on 01/02/2015 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. 25% of the shares subject to the option vested and became exercisable on 01/02/2016. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments. The option is exercisable as to 15,500 shares on 03/14/2023

(10) Grant to reporting person of Performance Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

(11) Represents an award of performance based restricted stock units ("PRSUs"). The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

(12) Each restricted stock unit represents a contingent right to receive one share of Isis common stock, or its equivalent cash value.

(13) The restricted stock units vest in four equal annual installments, the first installment vesting on January 15, 2021. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2024.

(14) The restricted stock units vest in four equal annual installments, the first installment vesting on January 15, 2022. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2025.

(15) The restricted stock units vest in four equal annual installments, the first installment vesting on January 15, 2023. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2026.

(16) The restricted stock units vest in four equal annual installments, the first installment vesting on April 15, 2022. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on April 15, 2026.

(17) The restricted stock units vest in four equal annual installments, the first installment vesting on January 15, 2023. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2027.

**Signature:** By: Patrick R. O'Neil, attorney-in-fact For: Brian Birchler  
**Date:** 2023-03-24

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**